Barbara L. Jones | Authors


Frontline Treatment Considerations in Non-Small Cell Lung Cancer

February 26, 2014

Although the current standard of care for advanced NSCLC remains platinum doublet chemotherapy, recent evidence suggests that most newly diagnosed patients may be candidates for targeted therapy as firstline treatment.

Model Emerges for Targeting Oncogenes in NSCLC

December 03, 2013

Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of NSCLC, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of ALK.